Top

11-03-2024 | Ritonavir | Original Article

The Impacts of Nirmatrelvir–Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic

Authors: Jun Gu, Zhi-Hua Han, Chang-qian Wang, Jun-feng Zhang

Published in: Cardiovascular Drugs and Therapy

Abstract

Purpose

Even though nirmatrelvir–ritonavir can improve the short-term morbidity and mortality in COVID-19 patients, the effects of this treatment on long-term major adverse cardiovascular events (MACEs), especially myocardial injury, remains undetermined.

Methods

This prospective cohort study identified hospitalized adult patients with COVID-19 between April 19, 2022, and June 9, 2022, amid the omicron wave of the pandemic. Matched nirmatrelvir–ritonavir-treated and non-treated cohorts were formed using the propensity score matching method. The primary outcome of this study was the incidence of MACEs (cardiovascular death, myocardial infarction, stroke, new-onset heart failure or heart failure hospitalization or ventricular arrhythmia) from 30 days to 16 months after the diagnosis of COVID-19.

Results

Two 949-patient cohorts with balanced baseline characteristics were formed by propensity score matching. Patients with nirmatrelvir–ritonavir, compared to those untreated, had a lower level of troponin I peak as well as the incidence of troponin I elevation. During the follow-up period, 59 patients in the nirmatrelvir–ritonavir group and 86 patients in the control group developed MACEs (P = 0.020). Regarding specific constituents of MACEs, the differences are mainly reflected in new-onset heart failure or heart failure hospitalization. COVID-19 clinical severity and troponin I peak were the independent predictors, while nirmatrelvir–ritonavir was the independent protective factor for the occurrence of MACEs in this population.

Conclusion

Nirmatrelvir–ritonavir was effective in reducing myocardial injury as well as long-term adverse cardiovascular outcomes among hospitalized patients with COVID-19 amid the omicron wave of the pandemic.

Giardina F, Ferrari G, Zavaglio F, et al. An overview of SARS-CoV-2 variants circulating in the 2020–2022 period in Lombardy. Diagn Microbiol Infect Dis. 2023;107(4):116070. https://doi.org/10.1016/j.diagmicrobio.2023.116070CrossRefPubMed

Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–58. https://doi.org/10.1038/s41569-020-0413-9CrossRefPubMedPubMedCentral

Chung MK, Zidar DA, Bristow MR, et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res. 2021;128(8):1214–36. https://doi.org/10.1161/CIRCRESAHA.121.317997CrossRefPubMedPubMedCentral

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.https://doi.org/10.1016/S0140-6736(21)00676-0

Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med. 2021;44:352–7. https://doi.org/10.1016/j.ajem.2020.04.052CrossRefPubMed

Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554–64. https://doi.org/10.1001/jamainternmed.2023.0743CrossRefPubMedPubMedCentral

Gu J, Yin ZF, Zhang JF, Wang CQ. Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension. Int J Cardiol. 2020;306:140–5. https://doi.org/10.1016/j.ijcard.2019.11.087CrossRefPubMed

Huang J, Cheng A, Lin S, Zhu Y, Chen G. Individualized prediction nomograms for disease progression in mild COVID-19. J Med Virol. 2020;92(10):2074–80. https://doi.org/10.1002/jmv.25969CrossRefPubMedPubMedCentral

Bürgi JJ, Rösslein M, Nolte O, et al. Mild COVID-19 induces early, quantifiable, persistent troponin I elevations in elder men. Front Cardiovasc Med. 2022;9:1053790. https://doi.org/10.3389/fcvm.2022.1053790CrossRefPubMedPubMedCentral

10.

Case BC, Shea C, Rappaport H, et al. The evolving impact of myocardial injury in patients with COVID-19 amid the omicron wave of the pandemic. Am J Cardiol. 2023;190:54–60. https://doi.org/10.1016/j.amjcard.2022.11.041CrossRefPubMed

11.

Mahabadi AA, Mincu R, Dykun I, et al. Frequency and prognosis of CVD and myocardial injury in patients presenting with suspected COVID-19 - the CoV-COR registry. Int J Cardiol Heart Vasc. 2023;45:101184. https://doi.org/10.1016/j.ijcha.2023.101184CrossRefPubMedPubMedCentral

12.

Villavicencio C, Daniel X, Ferré C, et al. Myocardial injury as a prognostic factor in critically ill patients with severe SARS-Cov-2 pneumonia. Med Intensiva (Engl Ed). 2023;47(1):48–51. https://doi.org/10.1016/j.medine.2022.05.016CrossRefPubMed

13.

Ababneh MJ, Al-Kasasbeh A, Jarrah M, et al. Myocardial injury and its correlation to mortality in hospitalized COVID-19 patients: a retrospective cohort study. Front Cardiovasc Med. 2022;9:1039655. https://doi.org/10.3389/fcvm.2022.1039655CrossRefPubMedPubMedCentral

14.

Rinaldi R, Basile M, Salzillo C, et al. Myocardial injury portends a higher risk of mortality and long-term cardiovascular sequelae after hospital discharge in COVID-19 survivors. J Clin Med. 2022;11(19):5964. https://doi.org/10.3390/jcm11195964CrossRefPubMedPubMedCentral

15.

Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5CrossRefPubMedPubMedCentral

16.

Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905–19. https://doi.org/10.1007/s10096-020-04138-6CrossRefPubMedPubMedCentral

17.

Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15. https://doi.org/10.1016/j.thromres.2020.11.012CrossRefPubMedPubMedCentral

18.

Saha SA, Russo AM, Chung MK, Deering TF, Lakkireddy D, Gopinathannair R. COVID-19 and cardiac arrhythmias: a contemporary review. Curr Treat Options Cardiovasc Med. 2022;24(6):87–107. https://doi.org/10.1007/s11936-022-00964-3CrossRefPubMedPubMedCentral

19.

Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. https://doi.org/10.1038/s41591-021-01283-zCrossRefPubMedPubMedCentral

20.

Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255–73. https://doi.org/10.1056/NEJMra2026131CrossRefPubMedPubMedCentral

21.

Siripanthong B, Asatryan B, Hanff TC, et al. The pathogenesis and long-term consequences of COVID-19 cardiac injury. JACC Basic Transl Sci. 2022;7(3):294–308. https://doi.org/10.1016/j.jacbts.2021.10.011CrossRefPubMedPubMedCentral

22.

Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–73. https://doi.org/10.1001/jamacardio.2020.3557CrossRefPubMedPubMedCentral

23.

Kotecha T, Knight DS, Razvi Y, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866–78. https://doi.org/10.1093/eurheartj/ehab075CrossRefPubMedPubMedCentral

24.

Vidula MK, Rajewska-Tabor J, Cao JJ, et al. Myocardial injury on CMR in patients with COVID-19 and suspected cardiac involvement. JACC Cardiovasc Imaging. 2023;16(5):609–24. https://doi.org/10.1016/j.jcmg.2022.10.021CrossRefPubMedPubMedCentral

25.

Liu TH, Chuang MH, Wu JY, et al. Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: a multicenter matched cohort study. J Med Virol. 2023;95(8):e28992. https://doi.org/10.1002/jmv.28992CrossRefPubMed

Title: The Impacts of Nirmatrelvir–Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic
Authors: Jun Gu
Zhi-Hua Han
Chang-qian Wang
Jun-feng Zhang
Publication date: 11-03-2024
Publisher: Springer US
Keywords: Ritonavir
COVID-19
Heart Failure
Published in: Cardiovascular Drugs and Therapy
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-024-07570-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

The Impacts of Nirmatrelvir–Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page